Amarin Corp Plc (AMRN)

[ziploc_1]

The Eisai-Biogen drug for Alzheimers has hit a snag...

.QUOTE..."Experimental Alzheimer's drug may have contributed to death of study participant, according to reports"

This monoclonal antibody drug seems to be effective in slowing Alzheimers...However it has serious side effects...such as swelling of the brain.. Also, It is necessary to be administered by infusion and it will be very expensive.

If EPA is shown by the Brave study to slow Alzheimers, it would be safer, less expensive, and more practical than a monoclonal antibody Rx. for Alzheimers.